Guillain-Barré syndrome
Conditions
Interventions
Efgartigimod group (Initiation of efgartigimod 10mg/kg, intravenous injection, administered twice within 5 days, within 10 days of limb weakness onset):None
IVIg group (Initiation of IVIg 0.4g/kg, intravenous injection, for 5 days, within 10 days of limb weakness onset):None
Sponsors
First Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: a) Provide a signed and dated informed consent form; b) Male or female, aged =18 years; c) Meet the diagnostic criteria for GBS; d) Able to run prior to the onset of GBS symptoms; e) GBS disability scale score = 3; f) Initiation of treatment with either efgartigimod (efgartigimod 10mg/kg, intravenous injection, administered twice within 5 days) or IVIg (0.4g/kg, intravenous injection, for 5 days) within 10 days of symptom onset (calculated from limb weakness).
Exclusion criteria
Exclusion criteria: a) GBS disability scale score = 2; b) Use of efgartigimod, IVIg, plasma exchange, rituximab, or immunosuppressants within 28 days prior to treatment with efgartigimod or IVIg; c) Combined use of efgartigimod and IVIg after the onset of GBS; d) Evidence supporting the diagnosis of other peripheral neuropathies; e) Presence of severe comorbidities affecting functional assessment, such as malignancies, severe cardiovascular diseases, severe chronic obstructive pulmonary disease (COPD), etc.; f) Onset of GBS symptoms more than 10 days prior.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Guillain-Barré Syndrome Disability Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| INCAT Disability Scale;I-RODS Scale;Grip strength;MRC sum scores; | — |
Countries
China
Contacts
Public ContactWei Zhang
First Hospital of Shanxi Medical University
Outcome results
None listed